KR20130140358A - 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 - Google Patents

살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 Download PDF

Info

Publication number
KR20130140358A
KR20130140358A KR1020120063665A KR20120063665A KR20130140358A KR 20130140358 A KR20130140358 A KR 20130140358A KR 1020120063665 A KR1020120063665 A KR 1020120063665A KR 20120063665 A KR20120063665 A KR 20120063665A KR 20130140358 A KR20130140358 A KR 20130140358A
Authority
KR
South Korea
Prior art keywords
carrier
dry powder
inhalation
particle size
inhalation formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020120063665A
Other languages
English (en)
Korean (ko)
Inventor
김경수
이덕규
김동호
김용일
박재현
우종수
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Priority to KR1020120063665A priority Critical patent/KR20130140358A/ko
Priority to AU2013275113A priority patent/AU2013275113A1/en
Priority to NZ703788A priority patent/NZ703788A/en
Priority to RU2015100905A priority patent/RU2015100905A/ru
Priority to BR112014030910A priority patent/BR112014030910A2/pt
Priority to IN11257DEN2014 priority patent/IN2014DN11257A/en
Priority to EP13804439.1A priority patent/EP2861219A4/en
Priority to MX2014014755A priority patent/MX2014014755A/es
Priority to SG11201408292YA priority patent/SG11201408292YA/en
Priority to HK15107131.8A priority patent/HK1206602A1/xx
Priority to PCT/KR2013/004880 priority patent/WO2013187626A1/en
Priority to US14/402,548 priority patent/US9283232B2/en
Priority to CA2876283A priority patent/CA2876283A1/en
Priority to JP2015517171A priority patent/JP2015519394A/ja
Priority to CN201380030898.0A priority patent/CN104363895A/zh
Priority to TW102120909A priority patent/TWI565481B/zh
Publication of KR20130140358A publication Critical patent/KR20130140358A/ko
Priority to PH12014502746A priority patent/PH12014502746B1/en
Priority to IL236198A priority patent/IL236198A0/en
Priority to ZA2015/00208A priority patent/ZA201500208B/en
Priority to US14/746,225 priority patent/US9549936B2/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020120063665A 2012-06-14 2012-06-14 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 Ceased KR20130140358A (ko)

Priority Applications (20)

Application Number Priority Date Filing Date Title
KR1020120063665A KR20130140358A (ko) 2012-06-14 2012-06-14 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
HK15107131.8A HK1206602A1 (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
CA2876283A CA2876283A1 (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
RU2015100905A RU2015100905A (ru) 2012-06-14 2013-06-03 Сухой порошок для ингаляционного препарата, включающий сальметерола ксинафоат, флутиказона пропионат и тиотропия бромид, а также способ его изготовления
BR112014030910A BR112014030910A2 (pt) 2012-06-14 2013-06-03 pó seco para formulação de inalação compreendendo xinafoato de salmeterol, propionato de fluticasona e brometo de tiotrópio e método para preparar o mesmo
IN11257DEN2014 IN2014DN11257A (enExample) 2012-06-14 2013-06-03
EP13804439.1A EP2861219A4 (en) 2012-06-14 2013-06-03 INHALED PREPARATION DRY POWDER COMPRISING SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND TIOTROPIUM BROMIDE, AND PREPARATION METHOD THEREOF
MX2014014755A MX2014014755A (es) 2012-06-14 2013-06-03 Polvo seco para formulacion para inhalacion que comprende xinafoato de salmeterol, propionato de fluticasona y bromuro de tiotropio, y metodo para su preparacion.
SG11201408292YA SG11201408292YA (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
AU2013275113A AU2013275113A1 (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
PCT/KR2013/004880 WO2013187626A1 (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
US14/402,548 US9283232B2 (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
NZ703788A NZ703788A (en) 2012-06-14 2013-06-03 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
JP2015517171A JP2015519394A (ja) 2012-06-14 2013-06-03 キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
CN201380030898.0A CN104363895A (zh) 2012-06-14 2013-06-03 用于吸入制剂的包含昔萘酸沙美特罗、丙酸氟替卡松和噻托溴铵的干粉及其制备方法
TW102120909A TWI565481B (zh) 2012-06-14 2013-06-13 包含沙美特羅羥萘甲酸鹽、弗提卡松丙酸鹽及托溴銨溴化物之吸入型調配物的乾粉末以及其製備方法
PH12014502746A PH12014502746B1 (en) 2012-06-14 2014-12-09 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
IL236198A IL236198A0 (en) 2012-06-14 2014-12-11 Dry powder for inhalation preparation containing salmatrol zinafoate, fluticasone propionate and tiotropium bromide, and its production method
ZA2015/00208A ZA201500208B (en) 2012-06-14 2015-01-13 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
US14/746,225 US9549936B2 (en) 2012-06-14 2015-06-22 Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120063665A KR20130140358A (ko) 2012-06-14 2012-06-14 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법

Publications (1)

Publication Number Publication Date
KR20130140358A true KR20130140358A (ko) 2013-12-24

Family

ID=49758405

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120063665A Ceased KR20130140358A (ko) 2012-06-14 2012-06-14 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법

Country Status (19)

Country Link
US (2) US9283232B2 (enExample)
EP (1) EP2861219A4 (enExample)
JP (1) JP2015519394A (enExample)
KR (1) KR20130140358A (enExample)
CN (1) CN104363895A (enExample)
AU (1) AU2013275113A1 (enExample)
BR (1) BR112014030910A2 (enExample)
CA (1) CA2876283A1 (enExample)
HK (1) HK1206602A1 (enExample)
IL (1) IL236198A0 (enExample)
IN (1) IN2014DN11257A (enExample)
MX (1) MX2014014755A (enExample)
NZ (1) NZ703788A (enExample)
PH (1) PH12014502746B1 (enExample)
RU (1) RU2015100905A (enExample)
SG (1) SG11201408292YA (enExample)
TW (1) TWI565481B (enExample)
WO (1) WO2013187626A1 (enExample)
ZA (1) ZA201500208B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016159542A1 (en) * 2015-03-31 2016-10-06 Hanmi Pharm. Co., Ltd. Capsule for inhalation with improved stability of combined active ingredients
KR20200078162A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
KR20210044336A (ko) * 2019-10-14 2021-04-23 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9360400B2 (en) 2014-06-30 2016-06-07 Proveris Scientific Corporation Sampling apparatus for determining the amount and uniformity of a delivered dose of drug and related methods
WO2016052897A1 (en) * 2014-09-30 2016-04-07 Hanmi Pharm. Co., Ltd. Dry powder for inhalation formulation having improved stability of combined active ingredients
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016178704A1 (en) * 2015-05-01 2016-11-10 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
WO2017156287A1 (en) * 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN108066329B (zh) * 2016-11-11 2021-11-16 江苏恒瑞医药股份有限公司 一种吸入用氟替卡松或其衍生物的微粒的制备方法
US11774363B2 (en) * 2018-08-07 2023-10-03 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
CN116033893A (zh) * 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂
CN115266987B (zh) * 2022-07-31 2023-06-30 浙江知一药业有限责任公司 治疗呼吸系统疾病的药物组合物
CN115792071B (zh) * 2022-12-01 2025-02-18 南京联智医药科技有限公司 一种噻格溴铵中间体的有关物质分析方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB0003935D0 (en) * 2000-02-08 2000-04-12 King S College London Formulation for dry powder inhaler
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
JP2010519195A (ja) * 2007-02-19 2010-06-03 シプラ・リミテッド 薬学的組成物
KR20100063116A (ko) * 2007-09-12 2010-06-10 글락소 그룹 리미티드 치료제들의 복합제
WO2010007446A1 (en) * 2008-07-18 2010-01-21 Prosonix Limited Process for improving crystallinity of fluticasone particles
AU2009276498A1 (en) * 2008-07-30 2010-02-04 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
TR201000681A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016159542A1 (en) * 2015-03-31 2016-10-06 Hanmi Pharm. Co., Ltd. Capsule for inhalation with improved stability of combined active ingredients
KR20160117069A (ko) 2015-03-31 2016-10-10 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입용 캡슐제
KR20200078162A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
KR20210044336A (ko) * 2019-10-14 2021-04-23 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법

Also Published As

Publication number Publication date
AU2013275113A1 (en) 2015-02-05
TW201402154A (zh) 2014-01-16
IN2014DN11257A (enExample) 2015-10-09
US20150157566A1 (en) 2015-06-11
HK1206602A1 (en) 2016-01-15
US9283232B2 (en) 2016-03-15
SG11201408292YA (en) 2015-01-29
ZA201500208B (en) 2016-10-26
BR112014030910A2 (pt) 2017-06-27
NZ703788A (en) 2016-10-28
RU2015100905A (ru) 2016-08-10
US9549936B2 (en) 2017-01-24
CN104363895A (zh) 2015-02-18
TWI565481B (zh) 2017-01-11
PH12014502746A1 (en) 2015-02-02
IL236198A0 (en) 2015-01-29
US20150283151A1 (en) 2015-10-08
WO2013187626A1 (en) 2013-12-19
CA2876283A1 (en) 2013-12-19
MX2014014755A (es) 2015-02-24
PH12014502746B1 (en) 2015-02-02
EP2861219A4 (en) 2015-10-28
EP2861219A1 (en) 2015-04-22
JP2015519394A (ja) 2015-07-09

Similar Documents

Publication Publication Date Title
KR20130140358A (ko) 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
CN105101955B (zh) 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物
CN104080444B (zh) 用于吸入给药包含皮质类固醇和beta‑肾上腺素能药物的干粉配制剂
CN107205936B (zh) 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
CN105338967A (zh) 包含布地奈德和福莫特罗的药物组合物
JP5154732B2 (ja) 薬剤
RU2823554C1 (ru) Новые частицы носителя для сухих порошковых составов для ингаляции
EP3203984B1 (en) Pharmaceutical composition containing budesonide and formoterol.
US12491156B2 (en) Carrier particles for dry powder formulations for inhalation
KR20180036459A (ko) 복합 활성성분의 개선된 함량 균일성 및 높은 단위전달량을 갖는 흡입용 캡슐제 및 이의 제조방법
HK40064779A (en) Novel carrier particles for dry powder formulations for inhalation
KR20160038767A (ko) 복합 활성성분의 안정성이 개선된 흡입 제형용 건조분말
HK1200021B (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20120614

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170524

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20120614

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180727

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181018

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180727

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I